| Budget Amount *help |
¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2019: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
Fiscal Year 2018: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Outline of Final Research Achievements |
Cancer stem cells (CSCs) are drug-tolerant and cause distant metastasis and recurrence in various cancers. Thus, CSC-targeted therapy may be an effective curative approach in CRC. In this study, we identified miR-1291 after screening of DCLK-1(doublecortin-like kinase 1) binding ability as a possible nucleic acid medicine against CSCs. MiR-1291 significantly suppressed the proliferation, invasion, migration, and colony formation capability of colon cancer cell lines. MiR-1291 caused altered expression of the cell cycle-regulatory proteins such as CDK inhibitors p21WAF1/CIP1 and p27KIP1, CDK4, CDK6, and cyclin E1, and CDC25A. We found that miR-1291 directly bound the 3’ UTR sequence of DCLK-1 and suppressed its expression at both the mRNA and protein levels. Moreover, miR-1291 suppressed CSC markers Bmi1 and CD133. Our data suggest that miR-1291 has an anti-tumor effect by modulating multiple functions, including invasiveness, cell cycle, and cancer stemness.
|
